1. INTRODUCTION
Liraglutide, a glucagon-like peptide 1 receptor (GLP-1) agonist that has been widely used for treatment of diabetes mellitus type 2, has also been associated with reduced risk for cardiovascular events in addition to lowering systolic blood pressure in patients with diabetes [1]. However, increased heart rate and reduced heart rate variability have been associated with liraglutide in patients with coronary artery disease and diabetes [2]. However, there is no knowledge of the effect of liraglutide on atrial fibrillation (AF) patients. In this study, we examined the effect of liraglutide in the AF patient population.